



# KMCH INSTITUTE OF HEALTH SCIENCES AND RESEARCH

(A unit of Kovai Medical Centre and Hospital Limited)

Coimbatore, Tamilnadu

SERIES 7  
FEB 2020

## DEPARTMENT OF PHARMACOLOGY- NEW DRUG UPDATE

S.No	Drug Name	Mechanism of Action	Indications	Adverse Drug Reactions	Dosage Formulation	Date of FDA Approval
1.	<b>Avapritinib</b>	Tyrosine kinase inhibition	Unresectable or metastatic Gastrointestinal stromal tumor harboring a platelet-derived growth factor receptor alpha exon 18 mutation	Edema, nausea, fatigue/asthenia, cognitive impairment, vomiting, decreased appetite, diarrhea, hair color changes, increased lacrimation, abdominal pain, constipation, rash and dizziness.	Tablet	09/01/2020
2.	<b>Teprotumumab-trbw</b>	Insulin-like growth factor-1 receptor inhibition	Thyroid eye disease	Muscle spasm, nausea, alopecia, diarrhea, fatigue, headache, hyperglycemia, hearing impairment, dry skin, dysgeusia	Intravenous Injection - Lyophilized powder in a single vial for reconstitution	21/01/2020
3.	<b>Tazemetostat</b>	Histone methyl transferase inhibition	Locally advanced Epithelioid sarcoma in adults and pediatric patients aged 16 years and older	Pain, fatigue, nausea, decreased appetite, vomiting, and constipation	Tablet	23/01/2020

### COMPILED & EDITED by

Department of Pharmacology  
KMCHHSR, Coimbatore, 641014

Kindly Mail Your Suggestions To:

[hodpharmacology@gmail.com](mailto:hodpharmacology@gmail.com)

Access this series  
through the KMCH website

[www.kmchhsr.edu.in](http://www.kmchhsr.edu.in)

Strive For Novelty